Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer

Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer - Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041507

Enrollment

400

Registered

2020-08-21

Start date

2020-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with non-squamous non-small cell lung cancer

Exclusion criteria

Exclusion criteria: Patients who have been diagnosed with malignant tumors other than non-squamous non-small cell lung cancer and have undergone chemotherapy for non-small cell lung cancer

Design outcomes

Primary

Measure	Time frame
Incidence, rates, severity and time to onset of adverse events, and treatment for adverse events	—

Countries

Japan

Contacts

Public ContactCHUGAI PHARMACEUTICAL CO., LTD.

Medical Affairs Div. Medical Science Dept.

cma-clinicaltrial@chugai-pharm.co.jp0332730866

Outcome results